Sugi Predict

Sugi Predict / Compounds / SCHEMBL798251

SCHEMBL798251

SCHEMBL798251

CC(=O)C1(CCCCCCCCCCCC2(CC(=O)O)CC2)CC1

nearest known ligand 0.41

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 2/20 0.37
▸ CYP4A11 Q02928 2/20 0.37
▸ CYP1A2 P05177 2/20 0.35
▸ USP2 O75604 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ BLM P54132 1/20 0.35
▸ CACNA2D1 P54289 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ CYP2C19 P33261 1/20 0.33
▸ KMT2A Q03164 1/20 0.32
▸ TBXAS1 P24557 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL798250 0.93 CYP1A2 (0.41) CYP4F2CYP4A11CYP1A2USP2ALDH1A1
SCHEMBL774169 0.85 CYP2C19 (0.44) CYP4F2CYP4A11CYP1A2USP2ALDH1A1
SCHEMBL773974 0.85 CYP2C19 (0.44) CYP4F2CYP4A11CYP1A2USP2ALDH1A1
SCHEMBL771954 0.84 CYP1A2 (0.45) CYP1A2USP2ALDH1A1LMNATSHR
SCHEMBL771865 0.84 CYP1A2 (0.45) CYP1A2USP2ALDH1A1LMNATSHR
SCHEMBL798378 0.83 CYP1A2 (0.38) CYP1A2USP2ALDH1A1LMNATSHR
SCHEMBL798046 0.83 CYP1A2 (0.38) CYP1A2USP2ALDH1A1LMNATSHR
SCHEMBL798303 0.82 CYP4F2 (0.47) CYP4F2CYP4A11TBXAS1
SCHEMBL798406 0.81 CYP4F2 (0.42) CYP4F2CYP4A11ALDH1A1
SCHEMBL23533422 0.79 GPR84 (0.45) ALDH1A1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230364039-A1 Methods of Managing Side Effects of a Vasopressin Receptor Antagonist Therapy UNIV EMORY (US) 2023-11-16 — — US disclosed
US-20140142178-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA KAREUS THERAPEUTICS, SA (CH) 2014-05-22 — — US disclosed
US-20140121267-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA KAREUS THERAPEUTICS, SA (CH) 2014-05-01 — — US disclosed
US-8623897-B2 Methods and compositions for treatment of diabetes and dyslipidemia KAREUS THERAPEUTICS, SA (CH) 2014-01-07 — — US disclosed
US-20120071528-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA KAREUS THERAPEUTICS, SA (CH) 2012-03-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071528-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA LIPC, PNLIP, LIPA CYP4F2 361/4885CYP4A11 66/4885CYP1A2 655/4885
US-20230364039-A1 Methods of Managing Side Effects of a Vasopressin Receptor Antagonist Therapy AVPR2, AVPR1A, AVPR1B CYP4F2 4874/4885CYP4A11 4735/4885CYP1A2 4628/4885
US-20140121267-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA GPR119, FFAR1, INSR CYP4F2 1151/4885CYP4A11 145/4885CYP1A2 699/4885
US-20140142178-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA DHCR7, INSR, GPR119 CYP4F2 1069/4885CYP4A11 289/4885CYP1A2 659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.